**FOR IMMEDIATE RELEASE**

## First Patient Enrolled in Phase IIb Clinical Trial of Rostafuroxin in Italy

Hong Kong, June 12, 2013 – Lee's Pharmaceutical Holdings Limited ("the Group") (Main Board Stock Code: 0950; Website: www.leespharm.com) today announced that the first patient for Rostafuroxin's global phase IIb clinical study has been enrolled.

Rostafuroxin is a digitoxygenin derivative that selectively disrupts the mutant adducin and theouabain-activated Na(+)/K(+)-pump binding to Src-SH2 domain without affecting the binding of normal proteins. Rostafuroxin is endowed of high potency and efficacy in reducing blood pressure and preventing organ hypertrophy in animal models representative of both adducin and EO mechanisms, by oral treatment. It is indicated for treatment of newly diagnosed hypertension patients who carry certain genetic profiles representative of adducing and EO-hypertensive mechanisms. The personalized treatment of hypertension could signify a shift of paradigm in hypertension treatment.

This is a global phase IIb multi-centers, double-blind, double-dummy, four-arms, parallel group, active comparator controlled clinical study. The study aims to using pharmacogenomics approach to evaluate the antihypertensive effect of different doses of Rostafuroxin in comparison with Losartan®, assessed by office and ambulatory blood pressure monitoring in a hypertensive population. The projected enrollment number is 320 patients (160 Caucasian and 160 Chinese), and today, the first patient has been enrolled at San Raffaele Hospital in Italy.

"We are delighted to have this important step for Rostafuroxin. This is a monumental achievement for CVie," said Dr. Benjamin Li, Chief Executive Officer of Lee's Pharmaceutical. "With the pre-IND meeting in China set at next month, we should be able to carry out this groundbreaking study swiftly."

**About Rostafuroxin**

**Rostafuroxin** is a digitoxygenin derivative that selectively disrupts the mutant adducin and theouabain-activated Na(+)/K(+)-pump binding to Src-SH2 domain without affecting the binding of normal proteins. Rostafuroxin is endowed of high potency and efficacy in reducing blood pressure and preventing organ hypertrophy in animal models representative of both adducin and EO mechanisms, by oral treatment. The understanding of the underlying genetic mechanisms of hypertension associated with the alpha-adducin Gly460Trp polymorphism and its interaction with ouabain has made pharmacogenomic approach for treatment of hypertension possible. It is indicated to treatment of newly diagnosed hypertension patients who carry certain genetic profiles representative of adducing and EO-hypertensive mechanisms. The personalized treatment of hypertension could signify a shift of paradigm in hypertension treatment.

**About Lee's Pharmaceutical**

**Lee's Pharmaceutical Holdings Limited** is a research-based Hong Kong biopharmaceutical company with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at www.leespharm.com.

**About CVie**

**CVie** is a joint venture between Lee's Pharmaceutical Holdings Ltd. and a reputable US venture capital and is a stand-alone drug development company specialized in cardiovascular diseases. CVie owns two phase II assets that target cardiovascular disease with significant unmet medical need. CVie has successfully filed to the CFDA the application for a global phase IIb clinical study in China for Rostafuroxin for hypertension in August 2012 and Istaroxime for acute decompensated heart failure in May 2013.

## ***Safe Harbor Statement***

*The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.*

*For further information, please contact: Vivian Fung*
*Tel: (852)2314-1282*
*Fax: (852)2314-1708*
*Email: info@leespharm.com*